Full text is available at the source.
Low-dose multivalent COVID-19 mRNA vaccines boost broad antibody response and improve protection when given with protein-based vaccines
Updated
Abstract
Essence
Low-dose multivalent SARS-CoV-2 mRNA vaccine combinations broadened antibody responses and boosted responses to coadministered protein-based vaccines in the tested system.
Evidence
This vaccine formulation and immunogenicity experiment compared low-dose trivalent mRNA, high-dose monovalent mRNA, variant spike proteins, and inactivated split influenza vaccine using cross-reactive IgG, receptor-binding inhibition, neutralization, immunogenicity, and influenza efficacy endpoints.
Caveat
The abstract does not identify the experimental model or report human clinical outcomes, so protective claims remain limited to the reported test system.
Simplified
mRNA Technology